Mechanism of action of camptothecin

Annals of the New York Academy of Sciences

Volumn 922, Issue , 2000, Pages 1-10

  Liu, L F ^a   Desai, S D ^a   Li, T K ^a   Mao, Y ^a   Sun, M ^a   Sim, S P ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CHEMOTHERAPY; CONFERENCE PAPER; CYTOTOXICITY; DNA DAMAGE; DRUG MECHANISM; HUMAN;

EID: 0034509633     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb07020.x     Document Type: Conference Paper

References (66)

1. Topoisomerase I-targeting drugs: New developments in cancer pharmacology
2. DNA topoisomerases: Essential enzymes and lethal targets
3. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
4. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin
5. New technique for uncoupling the cleavage and religation reactions of eukaryotic topoisomerase I. The mode of action of camptothecin at a specific recognition site
6. On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex
7. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA
8. A model for the mechanism of human topoisomerase I
9. DNA minor groove-binding ligands: A different class of mammalian DNA topoisomerase I inhibitors
10. Saintopin, a dual inhibitor of DNA topoisomerases I and II, as a probe for drug-enzyme interactions
11. Characterizing the DNA binding modes of a topoisomerase I-poisoning terbenzimidazole: Evidence for both intercalative and minor groove binding properties
12. A terbenzimidazole that preferentially binds and conformationally alters structurally distinct DNA duplex domains: A potential mechanism for topoisomerase I poisoning
13. Minor groove-directed and intercalative ligand-DNA interactions in the poisoning of human DNA topoisomerase I by protoberberine analogs
14. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials
15. Induction of topoisomerase I-mediated DNA cleavage by a new indolocarbazole, ED-110
16. DNA minor groove binding-directed poisoning of human DNA topoisomerase I by terbenzimidazoles
17. Differential poisoning of topoisomerases by menogaril and nogalamycin dictated by the minor groove-binding nogalose sugar
18. Benzo[a]pyrene diol epoxide adducts in DNA are potent suppressors of a normal topoisomerase I cleavage site and powerful inducers of other topoisomerase I cleavages
19. Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I
20. Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects
21. Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages. 7, 8-dihydro-8-oxoguanine and 5-hydroxycytosine
22. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons
23. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin
24. The involvement of active DNA synthesis in camptothecin-induced G2 arrest: Altered regulation of p34cdc2/cyclin B
25. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: Studies in a cell-free SV40 DNA replication system
26. A model for tumor cell killing by topoisomerase poisons
27. DNA topoisomerase-targeting antitumor drugs can be studied in yeast
28. NF-kappaB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events
29. Topoisomerase poisons activate the transcription factor NF-kappaB in ACH-2 and CEM cells
30. Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes
31. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen
32. Mechanism of action of camptothecin
33. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: Evidence for cell cycle-independent toxicity
34. Studies on camptothecin I: Effect on nucleic acid and protein synthesis
35. Effect of DNA-reactive drugs on RNA synthesis patterns in L1210 cells
36. The anti-cancer drug camptothecin inhibits elongation but stimulates initiation of RNA polymerase II transcription
37. Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes
38. Processing of topoisomerase I cleavable complexes into DNA damage by transcription
39. Hypersensitivity of Cockayne's syndrome cells to camptothecin is associated with the generation of abnormally high levels of double strand breaks in nascent DNA
40. Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity
41. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin
42. Yeast gene for a Tyr-DNA phosphodiesterase that repairs topoisomerase I complexes
43. SUMO-1 conjugation to topoisomerase I: A possible repair response to topoisomerase-mediated DNA damage
44. UBL1, a human ubiquitin-like protein associating with human RAD51/RAD52 proteins
45. PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia
46. A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex
47. SMT3A, a human homologue of the S. cerevisiae SMT3 gene, maps to chromosome 21qter and defines a novel gene family
48. Protection against Fas/APO-1 and tumor necrosis factor-mediated cell death by a novel protein, sentrin
49. A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2
50. Identification of the enzyme required for activation of the small ubiquitin-like protein SUMO-1
51. Multiple ubiquitin-conjugating enzymes participate in the in vivo degradation of the yeast MAT alpha repressor
52. Degradation signals for ubiquitin system proteolysis in Saccharomyces cerevisiae
53. Ubiquitin-dependent protein degradation
54. SUMO-1 modification of IkappaB-alpha inhibits NF-kappaB activation
55. Molecular characterization of the SUMO-1 modification of RanGAP1 and its role in nuclear envelope association
56. SUMO-1 modification and its role in targeting the Ran GTPase-activating protein, RanGAP1, to the nuclear pore complex
57. Ubc9p and the conjugation of SUMO-1 to RanGAP1 and RanBP2
58. Identification of three major sentrinization sites in PML
59. Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption
60. Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1
61. SUMO-1 modification activates the transcriptional response of p53
62. Cell cycle-specific and transcription-related phosphorylation of mammalian topoisomerase I
63. The roles of ubiquitin-dependent proteolysis in determining the sensitivity/resistance of tumor cells to topoisomerase inhibitors
64. The ubiquitin-proteasome pathway in cancer
65. Clinical evaluation of sequential topoisomerase targeting in the treatment of advance maligancy
66. Camptothecin resistance related to drug-induced down-regulation of topoisomerase I and to steps occurring after the formation of protein-linked DNA breaks